Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 4Retinoblastoma 4Wilms Tumor 3Medulloblastoma 3Liver Neoplasms 3Kidney Neoplasms 3Hepatoblastoma 3Central Nervous System Neoplasms 3Testicular Neoplasms 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Ovarian Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Desmoplastic Small Round Cell Tumor 2Carcinoma, Renal Cell 2Brain Neoplasms 2Astrocytoma 2Testicular Germ Cell Tumor 1Teratoma 1Sarcoma, Ewing 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1Neuroectodermal Tumors 1Neoplasms, Germ Cell and Embryonal 1Lymphoma 1Head and Neck Neoplasms 1Glioma 1Fibrosarcoma 1

Interventions

repotrectinib 1pralsetinib 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1cixutumumab 1Thiotepa 1Sunitinib 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Lutetium-177 1Lutetium 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Busulfan 1Bone Marrow Transplantation 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors × Thiotepa × Gastrointestinal × Clear all
NCT00003926 2017-11-29

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
13 enrolled
CNSGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcoma

Ovarian Germ Cell Cancer, Astrocytoma, Brain Neoplasms, Chordoma, Ependymoma, Glioma, Kidney Neoplasms, Liver Neoplasms, Medulloblastoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Neuroectodermal Tumors, Hepatoblastoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡